Healthcare Industry News: ZELTIQ
News Release - August 27, 2012
ZELTIQ(R) Aesthetics Intellectual Property and Patents Validated in Settlement against SkinSpaMedSettlement Follows Preliminary Injunction Against Dallas-Based Medical Spa
PLEASANTON, Calif.--(Healthcare Sales & Marketing Network)--ZELTIQ Aesthetics, Inc. (ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced it has accepted a settlement from SkinSpaMed. In February of this year, the United States District Court for the Northern District of Texas, Dallas Division, granted ZELTIQ a preliminary injunction prohibiting SkinSpaMed from issuing false and misleading statements regarding its imitation “Fat Freeze Cryolipolysis” services.
ZELTIQ is the exclusive licensee of Cryolipolysis, the patented technology behind the aesthetic procedure marketed as CoolSculpting®. Cryolipolysis is the non-invasive cooling of adipose tissue to induce lipolysis – the breaking down of fat cells – to reduce body fat without damage to other tissues.
“Whether in the United States or internationally, ZELTIQ is strongly committed to protecting its intellectual property rights and its reputation for safety and efficacy,” said Sergio Garcia, ZELTIQ Senior Vice President, General Counsel and Corporate Secretary. “To date, CoolSculpting is the only Cryolipolysis treatment that has received FDA clearance. Consumers should be aware of the potential dangers of non FDA-cleared copycat devices.”
ZELTIQ® Aesthetics, Inc. (ZLTQ) is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ’s first commercial product, the CoolSculpting® System, is designed to selectively reduce stubborn fat bulges that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. CoolSculpting utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer within a treated fat bulge without requiring the patient to diet or exercise.
Source: ZELTIQ Aesthetics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.